TY - JOUR T1 - Efficient Maternal to Neonatal transfer of SARS-CoV-2 and BNT162b2 antibodies JF - medRxiv DO - 10.1101/2021.03.31.21254674 SP - 2021.03.31.21254674 AU - Ofer Beharier AU - Romina Plitman Mayo AU - Tal Raz AU - Kira Nahum Sacks AU - Letizia Schreiber AU - Yael Suissa-Cohen AU - Rony Chen AU - Rachel Gomez-Tolub AU - Eran Hadar AU - Rinat Gabbay-Benziv AU - Yuval Jaffe Moshkovich AU - Tal Biron-Shental AU - Gil Shechter-Maor AU - Sivan Farladansky-Gershnabel AU - Hen Yitzhak Sela AU - Hedi Benyamini Raischer AU - Nitzan Dana Sela AU - Debra Goldman-Wohl AU - Ziv Shulman AU - Ariel Many AU - Haim Barr AU - Simcha Yagel AU - Michal Neeman AU - Michal Kovo Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/06/2021.03.31.21254674.abstract N2 - Background The significant risks posed to mothers and fetuses by COVID-19 in pregnancy have sparked a worldwide debate surrounding the pros and cons of antenatal SARS-CoV-2 inoculation, as we lack sufficient evidence regarding vaccine effectiveness in pregnant women and their offspring. We aimed to provide substantial evidence for the effect of BNT162b2 mRNA vaccine versus native infection on maternal humoral, as well as transplacentally acquired fetal immune response, potentially providing newborn protection.Methods A multicenter study where parturients presenting for delivery were recruited at 8 medical centers across Israel and assigned to three study groups: vaccinated (n=86); PCR confirmed SARS-CoV-2 infected during pregnancy (n=65), and unvaccinated non-infected controls (n=62). Maternal and fetal blood samples were collected from parturients prior to delivery and from the umbilical cord following delivery, respectively. Sera IgG and IgM titers were measured using Milliplex MAP SARS-CoV-2 Antigen Panel (for S1, S2, RBD and N).Results BNT162b2 mRNA vaccine elicits strong maternal humoral IgG response (Anti-S and RBD) that crosses the placenta barrier and approaches maternal titers in the fetus within 15 days following the first dose. Maternal to neonatal anti-COVID-19 antibodies ratio did not differ when comparing sensitization (vaccine vs. infection). IgG transfer rate was significantly lower for third-trimester as compared to second trimester infection. Lastly, fetal IgM response was detected in 5 neonates, all in the infected group.Conclusions Antenatal BNT162b2 mRNA vaccination induces a robust maternal humoral response that effectively transfers to the fetus, supporting the role of vaccination during pregnancy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementIsrael Science Foundation KillCorona grant 3777/19 (to MN, MK, SY, AM) Research grant from the Fondazione Henry Krenter (to MN) FERRING COVID-19 Investigational Grant in Reproductive Medicine and Maternal Health (RMMH) (to SY)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review boards of all participating medical centers and by the Weizmann Institute of Science. All research participants provided written informed consent prior to enrollment. The lead IRB overseeing this multicenter study was The Helsinki Committee at The Edith Wolfson Medical Center. Dr. Michal Kovo, the last author on the manuscript, is the lead PI on the protocol. The Approved protocol: 0107-20-WOMC.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made accessible after peer reviewed publication. ER -